Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 3/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120153 | 0.83 | MAPT (0.50) | SMN1; SMN2EPHX2MEN1KMT2ATRPV1 | |
| SCHEMBL2748592 | 0.80 | DYRK1A (0.44) | KDM4ESMN1; SMN2EPHX2 | |
| SCHEMBL5111541 | 0.79 | MEN1 (0.48) | SMN1; SMN2EPHX2MEN1KMT2AGAA | |
| SCHEMBL5127453 | 0.78 | NPC1 (0.40) | NPSR1KDM4ESMN1; SMN2EPHX2MEN1 | |
| SCHEMBL12377252 | 0.76 | EPHX2 (0.70) | EPHX2MEN1KMT2AFPR2TRPV1 | |
| SCHEMBL7113815 | 0.76 | LMNA (0.43) | EPHX2MEN1KMT2ACA12CA1 | |
| SCHEMBL2991244 | 0.76 | KIF11 (0.51) | EPHX2KMT2A | |
| SCHEMBL5126483 | 0.76 | KCNH3 (0.38) | NPSR1CA12CA1CA2 | |
| SCHEMBL4422986 | 0.73 | RXFP1 (0.43) | EPHX2TRPV1 | |
| SCHEMBL686377 | 0.72 | MAPT (0.49) | KDM4ESMN1; SMN2EPHX2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449493-B2 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMACEUTICAL COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-20050282882-A1 | Diamines as modulators of chemokine receptor activity | CARTER PERCY | 2005-12-22 | — | — | US | disclosed |
| US-6974836-B2 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1351924-A2 | DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Pharma Company (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-03-27 | — | — | US | disclosed |
| WO-2002050019-A2 | DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA CO. (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282882-A1 | Diamines as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | NPSR1 298/4885KDM4E 4271/4885SMN1; SMN2 2059/4885 |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | NPSR1 253/4885KDM4E 4236/4885SMN1; SMN2 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.